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Abstract The Mediator complex was originally discovered in yeast, but it is conserved in all eukaryotes. Its best-
known function is to regulate RNA polymerase II-dependent gene transcription. Although the mecha-
nisms by which the Mediator complex regulates transcription are often complicated by the context-
dependent regulation, this transcription cofactor complex plays a pivotal role in numerous biological
pathways. Biochemical, molecular, and physiological studies using cancer cell lines or model organisms
have established the current paradigm of the Mediator functions. However, the physiological roles of the
mammalian Mediator complex remain poorly deﬁned, but have attracted a great interest in recent
years. In this short review, we will summarize some of the reported functions of selective Mediator
subunits in the regulation of metabolism. These intriguing ﬁndings suggest that the Mediator complex
may be an important player in nutrient sensing and energy balance in mammals.
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INTRODUCTION
Gene transcription in eukaryotic cells is orchestrated
through extremely complicated processes and multiple
steps, including initiation, elongation, and termination,
with the initiation being the most studied regulation
step of gene expression. Disturbance of transcription
initiation often results in serious diseases, such as
cancer, in humans (Lee and Young 2013). Among the
numerous different components in the initiation step of
eukaryotic transcription, RNA polymerase II (Pol II) and
the general transcription factors (TFIIB, TFIID, TFIIE,
TFIIF, and TFIIH) constitute the basal transcription
machinery, and speciﬁc sets of transcription factors are
essential to determine the activation or repression of
the target genes. However, it is generally believed that
most of the transcription factors in eukaryotes are
unable to directly interact with Pol II, which is
responsible for the production of all mRNAs. Studies in
the past several decades suggest that this crucial gap is
often ﬁlled by various transcription cofactors, which
critically regulate the activation or repression in gene
expression.
There is no doubt that human beings are currently
experiencing an epidemic of obesity. As a result, the
prevalence of type 2 diabetes (T2D) has sharply
increased in the past decades. Dysregulation of genes in
the pathways controlling glucose and/or lipid metabo-
lism is common in states of insulin resistance and T2D,
especially when patients are also diagnosed with non-
alcoholic fatty liver disease (NAFLD) or cardiovascular
disease (Brown and Goldstein 2008; Oh et al. 2013). The
DNA-binding transcription factors and their cofactors
have been one focus of the studies in the hope of
understanding the molecular mechanisms that cause
metabolic diseases. A few notable examples of tran-
scription factors that regulate glucose and/or lipid
metabolism include cAMP-regulated enhancer-binding
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protein (CREB), forkhead O box proteins (FoxOs), glu-
cocorticoid receptor (GR), hepatic nuclear factors
(HNFs), sterol response element binding protein-1c
(SREBP-1c), carbohydrate response element binding
protein (ChREBP), liver X receptors (LXRs), and perox-
isome proliferator-activated receptor-c (PPARc) (Brown
and Goldstein 2008; Oh et al. 2013; Lefterova et al.
2014). Among the transcription cofactors, a multi-
subunit protein assembly called the Mediator complex
has been linked to several of these transcription factors
(Malik and Roeder 2010; Taatjes 2010; Conaway and
Conaway 2011; Allen and Taatjes 2015). Here, we
summarize the current understanding on the regulation
of transcription factors by individual subunits of the
Mediator complex, focusing mainly on the metabolic
involvement of the mediator subunits in mammals.
The Mediator complex as a transcription
cofactor
The Mediator complex is able to bind to various tran-
scription factors and integrates the transcriptional sig-
nals to the basal transcription machinery (Malik and
Roeder 2010; Taatjes 2010; Conaway and Conaway 2011;
Allen and Taatjes 2015). Originally discovered in yeast as
a transcription cofactor (Kelleher et al. 1990; Flanagan
et al. 1991; Kim et al. 1994), the mammalian Mediator
complex has been given several different names in the
early literature, including TRAP (thyroid hormone
receptor-associated protein) (Fondell et al. 1996), ARC
(activator-recruited cofactor) (Naar et al. 1999), or DRIP
(vitamin D receptor-interacting protein) (Rachez et al.
1998). In HeLa cells, the Mediator complex can be bio-
chemically isolated in at least two forms: the small
mediator, also known as the coremediator (with amass of
about 600 kDa), that comprises up to 26 subunits orga-
nized into the head, middle, and tail sub-modules, and the
large mediator (with a mass of about 1.2 MDa), which
additionally contains the kinase sub-module of four
subunits—cyclin-dependent kinase 8 (CDK8), cyclin C
(CycC),MED12, andMED13, but lacks theMED26 subunit
(Taatjes et al. 2002). However, in other studies only the
large Mediator complex was observed in the biochemical
puriﬁcations (Wang et al. 2001; Sato et al. 2004). Never-
theless, it is generally believed that theMediator complex
is heterogeneous both structurally and functionally. In
terms of functions, initial data suggested that the small
mediator functions to activate transcription initiation
in vitro, while the large mediator is inactive or acts as a
transcription repressor (Taatjes et al. 2002). However, the
large mediator has also been linked to transcription
elongation (Donner et al. 2010). In addition, the mediator
kinase module behaves in a context-speciﬁc manner to
either repress or activate transcription, depending on the
transcription factors and/or target gene promoters
(Nemet et al. 2014).
Since the Mediator complex can directly bind to Pol
II (Naar et al. 1999; Casamassimi and Napoli 2007;
Taatjes 2010; Soutourina et al. 2011; Lariviere et al.
2012), collectively it may regulate many genes. How-
ever, studies on individual subunits of the Mediator
complex revealed remarkable transcription factor and/
or tissue-speciﬁc functions for certain subunits. One
example is that the MED15 subunit binds to and reg-
ulates SREBP-dependent transcription, while the
MED25 subunit primarily controls VP16-mediated
transcription (Mittler et al. 2003; Yang et al.
2004, 2006). Although it is unclear how many tran-
scription factors could physically interact with the
Mediator complex, it is less likely that all transcription
factors need this complex to regulate target gene
expression. For instance, currently there is no evidence
that CREB or Myb can directly bind to the Mediator
complex, and depletion of some subunits such as
MED15 or MED25 had no effect on Myb-dependent
gene transcription in HEK293 cells (Yang et al.
2004, 2006). Moreover, the mediator subunit abun-
dance and/or subcellular location may be different
under different conditions. For example, feeding, obe-
sity, NAFLD, and aging can cause a signiﬁcant reduc-
tion of CDK8 and CycC proteins in the liver due to
mTORC1 activation (Feng et al. 2015). Another exam-
ple is that in response to stress, CycC undergoes
translocation from the nucleus to the cytoplasm to
regulate mitochondrial ﬁssion (Cooper et al. 2014;
Wang et al. 2015). Although little is known about how
the mediator subunit abundance is regulated, it may
alter the Mediator complex composition and thus may
have profound effects on the mediator-dependent
functions.
Recent structure studies have demonstrated the
presence of many different conformational assembly
states of the Mediator complex (Tsai et al. 2014;
Wang et al. 2014), indicating the intrinsic ﬂexibility
and heterogeneity. Moreover, the functions of the
Mediator complex are now expanded to include the
transcription elongation (Donner et al. 2010; Taka-
hashi et al. 2011) and termination (Mukundan and
Ansari 2011), and mRNA processing (Huang et al.
2012) and export (Schneider et al. 2015). Due to its
massive size and complexity, however, the precise
molecular mechanism(s) by which the Mediator com-
plex regulates the gene-speciﬁc transcription remain
poorly understood but are likely to play important
functional roles in both normal physiological and
pathophysiological states.
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The head module
The headmodule includesMED6,MED8,MED11,MED17,
MED18, MED20, MED22, MED27, MED28, MED29, and
MED30. This sub-module maintains the overall structure
of the Mediator complex. The importance of the head
module has been demonstrated from studies showing
that yeast loss of MED17 prevents nearly all mRNA syn-
thesis (Holstege et al. 1998; Thompson and Young 1995).
Although it is unclear whether MED17 plays a similarly
essential role inmammalian cells, a recent study reported
that MED17 in the liver regulates lipogenic gene expres-
sion and lipid metabolism through the LXR transcription
factors (Kim et al. 2015), providing a mechanism for the
mediator regulation of lipid metabolism. Moreover,
MED17 also binds to VP16, p53, and the estrogen
receptor (ER) (Burakov et al. 2000; Park et al. 2003;
Mehta et al. 2009;Meyer et al. 2010; Kumafuji et al. 2014).
Similarly, PPARc interacts with both MED1 (Zhu et al.
1997; Yuan et al. 1998; Ge et al. 2008) and MED14
(Grontved et al. 2010) subunits of the middle and tail
modules, respectively. Thus, it appears that a given
transactivation domain sometimes recruits the Mediator
complex by binding to more than one subunit.
It is the current understanding that the head and
middle modules may bind to either Pol II or the kinase
module in an exclusive manner (Knuesel et al. 2009a;
Naar et al. 2002). The head module is thought to provide
the greatest impact in controlling overall transcription
primarily by shifting the transcription machinery from
active to inactive state rather than serving as a binding
site for other transcriptional regulators. The electron
microscopy-derived structure and afﬁnity pull-down
experiments have identiﬁed MED17 as the main subunit
that directly interacts with Pol II and promotes the
transcription initiation of selected genes (Soutourina
et al. 2011). Interestingly, the head module subunit
MED30 is a metazoan-speciﬁc subunit, and a missense
mutation of MED30 in mice resulted in a pleiotropic
decrease in transcription of cardiac genes that are nec-
essary for oxidative phosphorylation and mitochondrial
integrity (Krebs et al. 2011). The mutation effect of
MED30 can be partially protected by a ketogenic diet
through increasing the expression of genes, such as
Pgc1a and Sod2 (Krebs et al. 2011). This study suggests a
critical role of MED30 in metabolism, but the regulatory
mechanism(s) shall be investigated in the future.
MED1 provides a docking surface for nuclear
receptors
The middle module includes subunits of MED1, MED4,
MED7, MED9, MED10, MED19, MED21 MED26, and
MED31. The MED26 subunit is a speciﬁc subunit of the
small mediator (Taatjes et al. 2002) and it is required
for transcription elongation (Takahashi et al. 2011). The
most studied subunit of the middle module is MED1, but
metabolic functions of other subunits in the middle
module remain to be investigated.
MED1 is able to interact with numerous transcription
factors or cofactors, including PPARa, PPARc, GR,
C/EBPb, and PGC1a, which are all implicated in meta-
bolic regulation (Zhu et al. 1997; Yuan et al. 1998) (See
Jia et al. 2014 for a recent review on MED1). Although
deletion of MED1 results in embryonic lethality at E11.5,
the MED1 conditional knockout or mutant mice play an
important role in adipogenesis through PPARc, fatty
acid oxidation through PPARa, mammary gland devel-
opment through ER, liver steatosis through GR and
constitutive androstane receptor (CAR), thermogenesis
regulation through uncoupling protein 1 (UCP1) up-
regulation, skeletal muscle function, and insulin signal-
ing (Ge et al. 2002; Jia et al. 2004, 2009; Jiang et al.
2010; Iida et al. 2015).
Similar to the steroid receptor co-activator (SRC) and
PGC1 families of transcription cofactors, MED1 contains
two LXXLL motifs [located within amino acid (aa)
589–593 and 630–634, respectively] that provide the
binding surfaces for various nuclear receptors, and
either one of the LXXLL motifs is sufﬁcient for protein–
protein interactions (Chang et al. 1999; Ge et al. 2008).
A dominant negative form of MED1 with mutant LXXLL
motifs reduces the transcription activity of nuclear
receptors and suppresses PPARc-induced adipogenesis
(Ge et al. 2002). However, these LXXLL motifs are not
required for MED1 regulation of PPARc in cultured
MEFs, suggesting MED1 regulation of gene transcription
through alternative mechanisms in a context-dependent
manner. Moreover, the conserved N-terminus (aa1–530)
of MED1 is also important for PPARc-target gene
expression (Ge et al. 2008). Deletion of MED1 in mouse
liver abrogates PPARa-activated peroxisomal prolifera-
tion (Jia et al. 2004) and acetaminophen-induced hep-
atotoxicity through CAR (Jia et al. 2005). Moreover,
liver-speciﬁc knockout of MED1 protects mice from
excessive fat accumulation under high-fat diet, whereas
the wild-type mice exhibited fatty liver (Bai et al. 2011).
Recently, MED1 has been found to interact with
PRDM16, a key inducer of brown adipose tissue (BAT)-
selective genes (Harms et al. 2015; Iida et al. 2015).
Directly interacting with the N-terminus of MED1,
PRDM16 promotes Ucp1 gene expression in brown
adipocytes (Iida et al. 2015). ChIP-Seq and ChIP-qPCR
analyses show that MED1 is recruited to the enhancer
sites of BAT-selective genes such as Ucp1, Cidea, Ppara,
and Pgc1a in the wild-type, but not in PRDM16
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knockout brown adipocytes (Harms et al. 2015). Fur-
thermore, skeletal muscle-speciﬁc knockout of MED1
increased gene expression of Ucp1 and Cidea, and pro-
moted mitochondrial density in white glycolytic skeletal
muscles and respiratory uncoupling (Chen et al. 2010).
The regulatory roles of MED1 in major metabolic
organs, such as liver, adipose tissues, and skeletal
muscle, suggest that MED1 is an important regulator for
metabolic gene expression. However, it is difﬁcult to
know whether the function(s) of MED1 are all mediator
dependent or not.
The tail module directly interacts with various
transcription factors
The tail module includes subunits of MED14, MED15,
MED16, MED23, MED24, and MED25. The metabolic
roles of this module are well established, particularly for
MED14, MED15, and MED23.
MED14 has been implicated in regulation of lipid
homeostasis. It has been reported that MED14 binds to
the N-terminal AF1 domain of GR (Hittelman et al.
1999) or PPARc (Grontved et al. 2010) to activate target
gene transcription. In vitro and in vivo assays show that
MED14 directly interacts with GR, and this interaction
increased GR-dependent transcription activation (Hit-
telman et al. 1999). In addition, MED14 directly inter-
acts with PPARc and promotes PPARc-dependent
transactivation as well as the recruitment of the Medi-
ator complex (Grontved et al. 2010). Recently, it has
been demonstrated that the Mediator complex is
recruited to the PPARc-target gene promoters without
the LXXLL motifs of MED1, suggesting that MED14 may
be more critically required for the transcription activa-
tion during adipogenesis (Grontved et al. 2010). Studies
of MED14 knockdown revealed that the recruitment of
PPARc, MED6, MED8, and Pol II to the transcription
start sites is dependent on MED14 in 3T3-L1 cells
(Grontved et al. 2010). At present, it is unclear what the
basis is for the apparent conﬂicting roles of MED1 and
MED14 in the regulation of PPARc-target genes. It
remains to be established whether these differences
reﬂect the different experimental interventions used,
differences in cells examined, or differential interactions
and physiologic outputs that occur during adipogenesis
versus fully differentiated adipocytes. In addition, there
may be undetermined cell-context effects resulting from
the secondary transcription factor interactions. For
example, MED14 was also reported to interact with the
SREBP transcription factors (Toth et al. 2004).
The functions of MED15 and other mediator subunits
in worms have been recently reviewed (Grants et al.
2015). In mammalian cells, MED15 acts as an important
regulator of lipid biosynthesis through modulating the
SREBPs (Yang et al. 2006). The interaction between
MED15 and SREBPs is through the MED15-KIX domain,
which is structurally similar to the KIX domains of CBP
and p300 (Yang et al. 2006). Interestingly, the KIX
domain of MED15 interacts only with SREBP-1a, but not
with several other transcription factors examined, sug-
gesting its binding speciﬁcity. The SREBP-target genes
include the important lipogenic and cholesterogenic
genes such as fatty acid synthase (Fasn) and HMG-CoA
synthase (Hmgcr) (Amemiya-Kudo et al. 2002). By
recruiting the Mediator complex upon binding to
SREBPs, MED15 promotes SREBP-target gene expres-
sion (Naar et al. 1998, 1999). Interestingly, small-
molecule inhibitors that block the interaction between
the MED15-KIX domain and the transactivation domain
of SREBP-1a protect mice from the metabolic dysregu-
lation that occurs during diet-induced obesity (Zhao
et al. 2014).
MED23 has been well studied in mammalian model
systems. The importance of MED23 in viability has been
shown with the embryonic lethality when MED23 was
knocked out in mice (Balamotis et al. 2009). MED23 has
been linked to insulin signaling in the adipogenesis
transcription cascade (Wang et al. 2009). In 3T3-L1
cells, it has been shown that the interaction of MED23
with Elk1 is enhanced by the insulin-induced MAPK
activation, resulting in further induction of Krox20, the
initial transcription factor in the adipogenesis pathway
(Wang et al. 2009). Interestingly, a recent study has
shown that MED23 is also involved in regulating the
differentiation of mesenchymal stem cells into smooth
muscle cells or adipocytes (Yin et al. 2012). MED23
deﬁciency promoted mesenchymal stem cells into
smooth muscle cells while preventing the differentiation
into adipocytes (Yin et al. 2012). The mechanism by
which MED23 controls the differentiation is via regu-
lating the balance of serum response factor (SRF)
downstream genes, RhoA/MAL or Ras/ELK1, by directly
interacting with them in response to upstream signals
(Stevens et al. 2002; Wang et al. 2009; Yin et al. 2012).
MED23 favors the ELK1–SRF complex formation, which
in turn facilitates the growth-related and adipogenic
genes and suppresses the cytoskeleton and smooth
muscle gene transcription (Yin et al. 2012). Further-
more, another recent report revealed that liver-speciﬁc
knockdown or knockout of MED23 signiﬁcantly
improved glucose and lipid metabolism, especially for
mice that were fed a high-fat diet (Chu et al. 2014).
Reduced FoxO1-target gene expression was found in
MED23-deﬁcient primary hepatocytes, demonstrating
that the regulation of MED23 on gluconeogenic gene
expression is through FoxO1 (Chu et al. 2014).
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Regulation of the balance between adipocyte and
smooth muscle development as well as hepatic lipid/
glucose metabolism by MED23 suggests the importance
of this subunit in metabolism.
It is known that HNF4a regulates a various set of
genes that are not only involved in early development
but also in liver and pancreatic cell differentiation,
glucose metabolism, and lipid homeostasis (Odom et al.
2004). In yeast two-hybrid assays, MED25 was found to
bind to HNF4a, inducing HNF4a-dependent gene tran-
scription that maintains the normal function of insulin
secretion in pancreatic b-cells (Odom et al. 2004). As a
subunit in the tail module, MED25 interaction with
HNF4a recruits the Mediator complex and Pol II for
transcriptional activation (Rana et al. 2011). Although
the exact mechanism is still unclear, these functional
studies also suggest a role of MED25 in metabolism and
lipid homeostasis.
The kinase module functions in a context-
dependent manner
Originally considered as a part of a transcriptional
repressor in the large Mediator complex, the kinase
module can repress or activate gene expression through
kinase-dependent or kinase-independent mechanisms
(Malik and Roeder 2010). Interestingly, the small
mediator subunit MED26 is present in a mutually
exclusive manner with CDK8 (Taatjes et al. 2002).
Moreover, the kinase activity of CDK8 is not always
required for its function in gene expression (Holstege
et al. 1998). Besides the four conserved subunits in this
module, paralogues have been identiﬁed for CDK8,
MED12, and MED13, i.e., CDK19, MED12L, and MED13L
(Daniels et al. 2013). Although their biological functions
are less clear, these paralogues are subunits of the
mammalian Mediator complex in a mutually exclusive
manner with CDK8, MED12, and MED13 (Daniels et al.
2013). Among the four subunits, the evolutionarily
conserved CDK8 and CycC have been studied for their
functions in lipogenic gene expression (Zhao et al.
2012). The tissue-speciﬁc CDK19 is highly similar to
CDK8 in amino acid sequence, but they may have both
overlapping and distinct functions (Tsutsui et al. 2011).
For instance, CDK8 but not CDK19 regulates HIF1-de-
pendent gene expression (Galbraith et al. 2013). Recent
studies also revealed the functional roles of MED12,
MED13, and MED13L in cardiovascular and systemic
metabolic regulation in both physiological and patho-
physiological states.
The CDK8–CycC dimer negatively regulates de novo
lipogenesis by reducing nuclear SREBP-1a or SREBP-1c
protein stability (Zhao et al. 2012). SREBP-1a and SREBP-1c
are key regulators of de novo lipogenesis, and post-
translational modiﬁcations represent critical mecha-
nisms that regulate their activity and/or abundance
(Brown and Goldstein 2008). In addition to acetylation/
deacetylation and ubiquitination, the phosphorylation of
nuclear forms of SREBP-1 is critical for the proteasome-
mediated degradation (Sundqvist et al. 2005). Therefore,
the direct phosphorylation of threonine 426 or 402 in
SREBP-1a and SREBP-1c isoforms, respectively, by CDK8
is important to understand the mechanism of SREBP-1
regulation of lipid metabolism (Zhao et al. 2012). The
functions of CDK8–CycC dimermaybe independent of the
Mediator complex, as up to 30% of CDK8 exists as a free
form from theMediator complex although the presence of
MED12 is required for maximal kinase activity of CDK8
(Knuesel et al. 2009b). Interestingly, insulin stimulation
in vitro and in vivo can reduce the protein levels of CDK8
and CycC (Zhao et al. 2012). In mouse livers, CDK8
knockdown increased the blood lipid levels and NAFLD-
like phenotypes (Zhao et al. 2012). Recent data have
further suggested that mTORC1 activation upon feeding
or in states of insulin resistance or NAFLD is responsible
for the down-regulation of CDK8 and CycC in the liver
(Feng et al. 2015).
In addition to CDK8 function in the negative regula-
tion of de novo lipogenesis through its kinase activity, it
has been shown that CDK8 has a positive role in
response to serum, likely at the elongation step instead
of the initiation step where CDK8 is a negative regulator
(Donner et al. 2010) (see (Nemet et al. 2014) for a recent
review). The difﬁculty of identiﬁcation of CDK8 sub-
strates in vivo lies with embryonic lethality of CDK8-
deﬁcient mice, whereas there is no effect on cell viability
in some cultured cells (Westerling et al. 2007). Never-
theless, using a selective inhibitor of CDK8 and CDK19 in
tissue culture, a recent study has added more potential
substrates of CDK8 and/or CDK19 to the increasing list
(Poss et al. 2016), which includes Cyclin H (Akoulitchev
et al. 2000), Notch (Fryer et al. 2004), histone H3
(Knuesel et al. 2009b), Smads (Alarcon et al. 2009),
SREBP-1 (Zhao et al. 2012), E2F1 (Zhao et al. 2013), and
STAT1 (Bancerek et al. 2013; Putz et al. 2013). However,
further studies are necessary to understand the roles of
CDK8 and CDK19 in metabolic regulation.
Through MED13, the MED12–MED13 dimer links the
small mediator as well as the CDK8–CycC dimer (Tsai
et al. 2013). Although the mechanism is unclear, MED12
can activate the Mediator complex-independent kinase
activity of CDK8 in vitro (Knuesel et al. 2009b). Inter-
estingly, MED13 in the heart regulates a subset of nuclear
hormone receptor target genes that are major determi-
nants of the metabolic rate and whole-body energy
expenditure (Grueter et al. 2012).MED13 overexpression
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in the heart resulted in an increase in energy expenditure
and resistance to diet-induced obesity (Grueter et al.
2012). MED13 is a target of miR-208a, one of the several
microRNAs that are encoded by the cardiac-speciﬁc a-
myosin heavy chain gene intron and are involved in heart
disease and metabolic regulation (Montgomery et al.
2011; Grueter et al. 2012). Inhibition of miR-208a resul-
ted in a similar metabolic phenotype that agrees with the
ﬁnding that miR-208a negatively regulates MED13
(Grueter et al. 2012). Elevated protein levels of MED13 in
the heart resulted in a signiﬁcant increase in oxygen
consumption, whereas the cardiac deletion of MED13
resulted in increased lipid accumulationwithout changes
in food intake in mice (Grueter et al. 2012). MED13, but
not MED13L, controls the whole-body metabolic home-
ostasis through altering metabolic proﬁles in white adi-
pose tissue and liver when MED13 is altered in the heart
(Baskin et al. 2014). Moreover, cardiac overexpression of
MED13 in mice improves dysregulation of energy meta-
bolism under high-fat diet likely through unknown cir-
culating factors, as determined by heterotypic parabiosis
experiments (Baskin et al. 2014). However, MED13
knockout in skeletal muscle resulted in resistance to
hepatic steatosis in mice by activating a metabolic gene
program that enhances muscle glucose uptake and stor-
age as glycogen (Amoasii et al. 2016). Mechanistically,
MED13 suppresses the expression of genes involved in
glucose uptake and metabolism in skeletal muscle by
inhibiting the nuclear receptor NURR1 and the MEF2
transcription factor (Amoasii et al. 2016). Although the
roles of MED13 in other metabolic tissues have not been
reported, the opposingmetabolic regulation byMED13 in
skeletal muscle and the heart further demonstrates the
tissue-speciﬁc functions of the Mediator complex.
To date, not much information is available on the
functions of MED12L and MED13L. Expressed in both
heart and brain, MED13L is associated with early
development of both heart and brain since its missense
mutations and gene interruption are found in patients
with congenital heart defect, learning disabilities, and
facial anomalies (Muncke et al. 2003; Asadollahi et al.
2013; Davis et al. 2013). Both MED13 and MED13L are
degraded by the SCF/Fbw7-dependent ubiquitination
mechanism, and similar to MED13, MED13L may be also
responsible for linking the kinase module to the small
Mediator complex (Davis et al. 2013).
CONCLUSION
Since the discovery of the Mediator complex as a tran-
scription cofactor of eukaryotes, its subunits have been
associated with various biological processes and several
diseases ranging from developmental defects to cancer
in animal models and humans. The metabolic functions
of the Mediator complex have become increasingly sig-
niﬁcant. In most cases, the Mediator complex functions
as a bridge to connect and integrate speciﬁc transcrip-
tion factors to the basal transcription machinery,
resulting in expression changes of a selective set of
genes. In addition to the presence of many subunits,
tissue-speciﬁc expression and possible diverse assembly
states at different physiological conditions further
complicate the biological functions of the Mediator
complex. Future studies on the role of the Mediator
complex in metabolism may include identiﬁcation of
how the metabolic or nutrient signals may regulate the
assembly states and subunit compositions and investi-
gation of tissue-speciﬁc functions of each subunit in
regulating nutrient and energy metabolism in vivo.
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